Is Alprazolam Anticholinergic?
No, alprazolam is not clinically anticholinergic and does not possess significant anticholinergic properties that would contribute to anticholinergic burden in patients.
Pharmacological Evidence
Alprazolam is a benzodiazepine that works through GABA-A receptor modulation, not through muscarinic receptor blockade 1. The FDA label clearly describes its mechanism as binding at stereospecific benzodiazepine receptors within the central nervous system, producing dose-related CNS depression without mentioning anticholinergic activity 1.
Clinical Distinction from Anticholinergic Medications
The 2021 Mayo Clinic guidelines on polypharmacy management explicitly list strongly anticholinergic medications that should be deprescribed in older adults—including diphenhydramine, cyclobenzaprine, and oxybutynin—but benzodiazepines are discussed separately as sedating medications, not as anticholinergic agents 2. This distinction is critical: while both drug classes can impair cognition and increase fall risk in elderly patients, they do so through entirely different mechanisms.
Research Evidence Clarifies the Picture
A 1985 comparative study directly addressed this question: when comparing alprazolam to the tricyclic antidepressants amitriptyline and doxepin, anticholinergic effects were reported significantly more frequently with the tricyclics but NOT with alprazolam 3. This head-to-head comparison provides clear evidence that alprazolam lacks the clinically relevant anticholinergic properties seen with truly anticholinergic medications.
While one 2012 study found that some benzodiazepines can inhibit acetylcholine-receptor-operated potassium currents in guinea pig atrial myocytes 4, this in vitro cardiac electrophysiology finding does not translate to the classic anticholinergic syndrome (dry mouth, urinary retention, constipation, blurred vision, cognitive impairment from muscarinic blockade) seen with anticholinergic medications in clinical practice.
Clinical Implications
- Do not count alprazolam toward anticholinergic burden scores when assessing polypharmacy risk
- Alprazolam's cognitive and functional impairment in elderly patients stems from its sedative and GABAergic effects, not anticholinergic mechanisms 2
- When deprescribing in older adults, address alprazolam as a high-risk benzodiazepine (due to dependence, falls, sedation) rather than as an anticholinergic agent
- The Drug Burden Index mentioned in guidelines includes both sedating AND anticholinergic medications as separate categories—alprazolam falls into the former 2
Important Caveat
While alprazolam is not anticholinergic, it remains a high-risk medication in older adults due to its potent sedative effects, rapid onset, short half-life promoting dependence, and association with falls, confusion, and functional decline 5, 6. These risks should not be minimized simply because the drug lacks anticholinergic properties.